These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mycophenolate mofetil for ocular inflammation. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH. Am J Ophthalmol; 2010 Mar; 149(3):423-32.e1-2. PubMed ID: 20042178 [Abstract] [Full Text] [Related]
8. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis]. Greiner K, Varikkara M, Santiago C, Forrester JV. Ophthalmologe; 2002 Sep; 99(9):691-4. PubMed ID: 12219257 [Abstract] [Full Text] [Related]
9. Mycophenolate mofetil for the treatment of uveitis. Teoh SC, Hogan AC, Dick AD, Lee RW. Am J Ophthalmol; 2008 Nov; 146(5):752-60, 760.e1-3. PubMed ID: 18455143 [Abstract] [Full Text] [Related]
10. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M. Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):788-94. PubMed ID: 16163494 [Abstract] [Full Text] [Related]
11. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Lau CH, Comer M, Lightman S. Clin Exp Ophthalmol; 2003 Dec; 31(6):487-91. PubMed ID: 14641155 [Abstract] [Full Text] [Related]
12. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Androdias G, Maillet D, Marignier R, Pinède L, Confavreux C, Broussolle C, Vukusic S, Sève P. Neurology; 2011 Mar 29; 76(13):1168-72. PubMed ID: 21444902 [Abstract] [Full Text] [Related]
13. Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. Bert A, El Jammal T, Kodjikian L, Gerfaud-Valentin M, Jamilloux Y, Seve P. Ocul Immunol Inflamm; 2024 Feb 29; 32(2):154-160. PubMed ID: 36749910 [Abstract] [Full Text] [Related]
14. Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease. Cuchacovich M, Solanes F, Perez C, Verdaguer JI, Verdaguer J, Castiglione E, Carpentier C, Traipe L, Villarroel F. J Ocul Pharmacol Ther; 2016 Feb 29; 32(1):55-61. PubMed ID: 26562247 [Abstract] [Full Text] [Related]
15. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Chang PY, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS. Eye (Lond); 2011 Apr 29; 25(4):427-35. PubMed ID: 21423146 [Abstract] [Full Text] [Related]
16. Mycophenolate mofetil in the therapy of uveitic macular edema--long-term results. Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Deuter C. Ocul Immunol Inflamm; 2012 Jun 29; 20(3):203-11. PubMed ID: 22489750 [Abstract] [Full Text] [Related]
17. [Mycophenol acid in ocular automimmune disorders--can we optimise this therapy?]. Pleyer U, Ruokonen P, Schmidt N, Feist E, Höhne M, Stanojlovic S. Klin Monbl Augenheilkd; 2008 Jan 29; 225(1):66-9. PubMed ID: 18236373 [Abstract] [Full Text] [Related]
18. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB, Thorne JE. Ophthalmology; 2008 Oct 29; 115(10):1826-32. PubMed ID: 18579209 [Abstract] [Full Text] [Related]
19. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. Li J, Kelly R. J Am Acad Dermatol; 2013 Oct 29; 69(4):565-9. PubMed ID: 23850090 [Abstract] [Full Text] [Related]
20. Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis. Hedayatfar A, Falavarjani KG, Soheilian M, Elmi Sadr N, Modarres M, Parvaresh MM, Naseripour M, Rohani M, Almasi M, Chee SP. Ocul Immunol Inflamm; 2017 Jun 29; 25(3):308-314. PubMed ID: 27379567 [Abstract] [Full Text] [Related] Page: [Next] [New Search]